#AnaptysBio

星良孝 Yoshitaka Hoshi

@yoshitakahoshi.bsky.social

3 months ago

GSK子会社TESARO、ドスタルリマブを巡りAnaptysBioを提訴 契約違反によりライセンス終了を主張 | STELLANEWS.LIFE TESARO（GSKの子会社）は、がん免疫薬ドスタルリマブ（商品名ジェンペルリ）のライセンス契約を巡り、AnaptysBioに対する訴訟をデラウェア衡平法裁判所で開始した。TESARO側は契約違反を主張し、永久的な使用権獲得とロイヤルティ支払いの半減を求めている。AnaptysBioによるライセンス取り消しの主張に対しては、根拠がないと反論している。

TESARO, a GSK subsidiary, sues AnaptysBio over the dostarlimab (Jemperli) license agreement.

🔗 Full article: stellanews.life/technology_c...

#GSK #TESARO #AnaptysBio #Jemperli #Dostarlimab #LegalDispute #Oncology #Immunotherapy #Pharma

星良孝 Yoshitaka Hoshi

@yoshitakahoshi.bsky.social

3 months ago

【GSK子会社TESARO、ドスタルリマブを巡りAnaptysBioを提訴】
GSKの子会社TESAROが、がん免疫療法薬ドスタルリマブ（Jemperli）に関するライセンス契約違反を理由に、AnaptysBioを提訴したと発表。

#GSK #TESARO #AnaptysBio #Jemperli #ドスタルリマブ #がん免疫療法 #契約訴訟 #バイオ医薬品 #ライセンス契約

pharmaphorum

@pharmaphorum.bsky.social

3 months ago

GSK unit and AnaptysBio trade lawsuits over Jemperli A spat between GSK/Tesaro and AnaptysBio over cancer drug Jemperli has escalated into litigation, with both parties claiming breach of contract.

#GSK has escalated a dispute over rights to its cancer #immunotherapy Jemperli, after its subsidiary #Tesaro filed a complaint against #AnaptysBio in the #DelawareCourt of Chancery, alleging #breachofcontract.

pharmaphorum.com/news/gsk-uni...

PRISM MarketView

@prismmarketview.bsky.social

9 months ago

AnaptysBio Reports Positive Six-Month Data for Potential Best-in-Class Rheumatoid Arthritis Therapy Phase 2b trial shows durable clinical responses, favorable safety, and monthly dosing convenience AnaptysBio (Nasdaq: ANAB) announced new six-month data from

#ANAB has reported positive six-month data for its potential best-in-class RA therapy, showing strong efficacy and safety. A hopeful step forward for millions living with chronic inflammation.
#AnaptysBio
prismmarketview.com/anaptysbio-r...

Thiard News@F4F

@newsen.bsky.social

1 year ago

Vanda Pharmaceuticals and AnaptysBio Partner for Imsidolimab's Global Development in Psoriasis Treatment Vanda Pharmaceuticals and AnaptysBio have partnered to develop Imsidolimab, targeting Generalized Pustular Psoriasis, after successful Phase 3 trials.

Vanda Pharmaceuticals and AnaptysBio Partner for Imsidolimab's Global Development in Psoriasis Treatment #USA #Washington #Vanda_Pharmaceuticals #Imsidolimab #AnaptysBio